Chat with an Expert

ImmunoCult™ Human Treg Differentiation Supplement

Serum-free culture supplement for the differentiation of human naïve CD4+ T cells into regulatory T cells (Tregs)

More Views

ImmunoCult™ Human Treg Differentiation Supplement

Culture supplement for the differentiation of human naïve CD4+ T cells into Tregs

1 mL
Catalog #10977
219 USD

Overview

ImmunoCult™ Human Treg Differentiation Supplement contains a human cytokine and small molecule formulated to promote the robust activation, expansion, and differentiation of peripheral blood-derived, naïve, CD4+ human T cells into regulatory T cells (Tregs). ImmunoCult™ Human Treg Differentiation Supplement is intended for use with ImmunoCult™-XF T Cell Expansion Medium and ImmunoCult™ Human CD3/CD28 T Cell Activator.

This product is recommended for:
• Research into the regulation of human naïve T cell differentiation and Treg function
• Development of procedures to expand and polarize naïve T cells into Tregs
Advantages:
• Formulated for the induction of human Treg differentiation
• Optimized for use with ImmunoCult™-XF T Cell Expansion Medium
• Supports higher levels of memory T cells in comparison to competitor Treg differentiation kit
• Supports up to 20% higher proportions of CD4+CD25+FOXP3+T cells in comparison to competitor Treg differentiation kit
• Supplied as a 50X concentrate; after thawing and mixing, the tube contents can be added directly to medium
Contains:
• Recombinant human TGF-β1
• All-trans retinoic acid
Subtype:
Supplements
Cell Type:
T Cells; T Cells, CD4+
Species:
Human
Application:
Cell Culture; Expansion; Differentiation
Brand:
ImmunoCult
Area of Interest:
Immunology

Scientific Resources

Educational Materials

(5)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

Figure 1. ImmunoCult™ Human Treg Differentiation Supplement Produces Differentiated CD4+CD45RA-CD45RO+ Cells Under Treg Polarizing Conditions

Naïve CD4+ T cells were isolated from human peripheral blood samples using the EasySep™ Human Naïve CD4+ T Cell Isolation Kit (Catalog #19555). Cells were stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator (Catalog #10971) and ImmunoCult™ Human Treg Differentiation Supplement (Catalog #10977), cultured in ImmunoCult™-XF T Cell Expansion Medium (Catalog #10981) for 7 days. Shown are flow cytometry results of cell samples stained and analyzed for expression of CD45RA and CD45RO (A) before and (B) after 7 days of culture. After 7 days the majority of Treg cells in culture display a memory T cell phenotype (CD45RA-CD45RO+).

Figure 2. ImmunoCult™ Human Treg Differentiation Supplement Produces Similar Numbers of Differentiated CD4+CD45RA-CD45RO+ Cells Under Treg Polarizing Conditions Than Competitor

Naïve CD4+ T cells were isolated from human peripheral blood samples using the EasySep™ Human Naïve CD4+ T Cell Isolation Kit (Catalog #19555) and cultured with ImmunoCult™ Human CD3/CD28 T Cell Activator (Catalog #10971) and ImmunoCult™ Human Treg Differentiation Supplement (Catalog #10977) in ImmunoCult™-XF T Cell Expansion Medium (Catalog #10981) (purple), or competitor medium and activator (grey) for 5 days (based on the length of the competitor protocol). The percentage of naïve (CD45RA+CD45RO-) and differentiated (CD45RA-CD45RO+) cells after culture was compared after staining cells for CD45RA and CD45RO and analysis by flow cytometry. The percentage of cells expressing a naïve phenotype and the percentage of cells expressing a differentiated phenotype were not significantly higher with ImmunoCult™ than with competitor medium and activator. Shown are the differences in the percentage of naïve and differentiated T cells in either ImmunoCult™ (purple) and competitor (grey) culture conditions (mean ± S.E.M.; paired t-test on logit transformed data; n = 4).

Figure 3. ImmunoCult™ Human Treg Differentiation Supplement Produces FOXP3+ Cells Under Treg Polarizing Conditions

Naïve CD4+ T cells were cultured for 7 days in ImmunoCult™ activator, supplement and medium using the protocol described in Figure 2. Cells were stained for CD4, CD4, CD25 and FOXP3 and analyzed on days 0, 4, 5 and 7 by flow cytometry. Each bar represents the mean percentage of CD3+CD4+ cells expressing both CD25 and FOXP3 (CD3+CD4+CD25+FOXP3+) (mean ± S.E.M; n = 4 – 20 donors).

Figure 4. Culture with ImmunoCult™ Human Treg Differentiation Supplement Produces Similar Percentages of CD3+CD4+CD25+FOXP3+ Cells as Culture Under Competitor Conditions

Naïve CD4+ T cells were cultured for 5 days in ImmunoCult™ activator, supplement and medium, or competitor medium and activator using the protocol described in Figure 2. The percentage of CD25+FOXP3+ after 5 days of culture was compared after staining cells for CD3, CD4, CD25 and FOXP3 and analysis by flow cytometry. Similar percentages of CD3+CD4+ cells generated with ImmunoCult™ expressed CD25 and FOXP3 as compared to those generated under competitor conditions. Shown are the differences in the percentage of CD3+CD4+ cells expressing both CD25 and FOXP3 (CD3+CD4+CD25+FOXP3+) in either ImmunoCult™ (purple) and competitor (grey) culture conditions (mean ± S.E.M.; paired t-test on logit transformed data; n = 4 - 20).

STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.